All patients
age >= 60 yr age >= 65 yr corticosteroids: no corticosteroids: yes invasive ventilation non invasive oxygen subjects at risk
antiviral and associated therapy in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias death D28detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
0.97 [0.73 ; 1.29 ] COALITION II Covid-19 Brazil (Furtado), 2020, HYDRA (Hernandez-Cardenas), 2021 2 16% 611 moderate not evaluable deathsdetailed results Cao, 2020 0.71 [0.36; 1.40]
CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
0.85 [0.71 ; 1.01 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 6 11% 2,097 moderate not evaluable deaths (time to event analysis only)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.08 [0.79; 1.47]
HYDRA (Hernandez-Cardenas), 2021 0.80 [0.52; 1.24]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.65; 1.06]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.58 [0.36; 0.93]
0.84 [0.67 ; 1.05 ] COALITION II Covid-19 Brazil (Furtado), 2020, HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 4 39% 1,662 moderate not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
0.95 [0.55 ; 1.64 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvementdetailed results Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
0.96 [0.68 ; 1.35 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 4 68% 1,040 moderate not evaluable clinical improvement (14-day)detailed results Cao, 2020 1.94 [1.09; 3.48]
CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
COALITION II Covid-19 Brazil (Furtado), 2020 0.74 [0.51; 1.07]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.85 [0.64; 1.12]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.37; 1.06]
0.94 [0.68 ; 1.30 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 5 62% 1,883 moderate not evaluable clinical improvement (28-day)detailed results Cao, 2020 1.59 [0.84; 3.03]
CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
COALITION II Covid-19 Brazil (Furtado), 2020 0.70 [0.47; 1.04]
1.10 [0.64 ; 1.90 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 3 68% 832 moderate not evaluable clinical improvement (7-day)detailed results Cao, 2020 3.16 [0.62; 16.06]
CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
COALITION II Covid-19 Brazil (Furtado), 2020 0.94 [0.63; 1.40]
1.01 [0.68 ; 1.50 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 3 1% 832 moderate not evaluable clinical improvement (time to event analysis only)detailed results Cao, 2020 1.31 [0.94; 1.83]
CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
HYDRA (Hernandez-Cardenas), 2021 1.05 [0.74; 1.48]
1.19 [0.98 ; 1.45 ] Cao, 2020, CAP-China (Wang et al.), 2020, HYDRA (Hernandez-Cardenas), 2021 3 0% 451 moderate not evaluable hospital dischargedetailed results HYDRA (Hernandez-Cardenas), 2021 1.01 [0.72; 1.42]
REMAP-CAP (lopinavir/ritonavir only), 2020 0.83 [0.69; 1.00]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.63 [0.43; 0.92]
0.82 [0.66 ; 1.02 ] HYDRA (Hernandez-Cardenas), 2021, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 3 40% 1,265 moderate not evaluable off oxygenationdetailed results HYDRA (Hernandez-Cardenas), 2021 0.98 [0.64; 1.51]
0.98 [0.64 ; 1.51 ] HYDRA (Hernandez-Cardenas), 2021 1 0% 214 NA not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable related SAE (TRSAE)detailed results COALITION II Covid-19 Brazil (Furtado), 2020 1.24 [0.50; 3.11]
1.24 [0.50 ; 3.11 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable serious adverse eventsdetailed results Cao, 2020 0.52 [0.27; 1.01]
CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
COALITION II Covid-19 Brazil (Furtado), 2020 1.20 [0.82; 1.77]
REMAP-CAP (lopinavir/ritonavir only), 2020 1.57 [0.70; 3.49]
REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 0.97 [0.22; 4.33]
0.90 [0.59 ; 1.38 ] Cao, 2020, CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020, REMAP-CAP (lopinavir/ritonavir only), 2020, REMAP-CAP (lopinavir/ritonavir plus hydroxychloroquine), 2020 5 47% 1,872 moderate not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
0.36 [0.13 ; 1.01 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
1.09 [0.42 ; 2.79 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable long QTdetailed results COALITION II Covid-19 Brazil (Furtado), 2020 0.90 [0.56; 1.43]
0.90 [0.56 ; 1.43 ] COALITION II Covid-19 Brazil (Furtado), 2020 1 0% 439 NA not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
COALITION II Covid-19 Brazil (Furtado), 2020 1.44 [0.99; 2.11]
1.44 [0.98 ; 2.10 ] CAP-China (Wang et al.), 2020, COALITION II Covid-19 Brazil (Furtado), 2020 2 0% 672 moderate not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2025-03-09 03:31 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 91
- treatments: 545,1253,519,619,537,514,688,529,508,656,657,832,530,512,515,754,1142,1419,513,884,632,559,889,956,684,886,631,574,509,542,1145,555,554,941,961,1250,633,676,518,532,510,528,520,955,815,893,623,622,630,593,569,516,814
- roots T: 290
